Page 26 - GTM-2-2
P. 26

Global Translational Medicine                                     Use of cardio biomarker in diagnosis of AMI














































            Figure 3. Biosensor for diagnosing acute myocardial infarction.

            including cTnl, and activated by an integrated optical   enable the rapid identification and early detection of AMI,
            waveguide made of silicon oxynitride.              resulting in better patient outcomes and immediate medical
              In a multianalyte platform like this, many biomarkers   intervention. Myoglobin, cardiac troponins, and CK are
            are simultaneously detected, and due  to their high   examples of cardiac biomarkers that are frequently used
            sensitivity, this sort of biochip can act as a POC apparatus.   to identify AMI. Biosensors based on principles such as
            Markers that can be detected in ELISA-based assays   fluorescence, auditory, and colorimetry have also been found
            such as cTnl may be detected using a colorimetric and   to be promising diagnostic methods for AMI. AMI diagnosis
            fluorescent immunoassay. These assays are quick and have   has also been proven to be more sensitive and specific when
            great sensitivity, but the procedures involved are time-  biomarkers linked to oxidative stress and inflammation,
            consuming and laborious (Figure 3) [63-66] .       such as MMPs and MPO, are used. Further, development of
                                                               cardiac biomarkers and biosensors might generate even more
            6. Conclusions                                     precise and effective AMI detection methods in the future.
            The utility of cardiac biomarkers and biosensors in AMI   Acknowledgments
            diagnosis  cannot  be  overstated.  The  high  specificity  and
            sensitivity  of  cardiac  troponin, connected with advances   None.
            in biosensor technology, have significantly improved
            diagnostic  accuracy.  Biosensors,  such  as  electrochemical   Funding
            and optical biosensors, offer rapid and precise detection of   None.
            cardiac biomarkers, enabling timely intervention of diseases.
                                                               Conflict of interest
              Diagnosis of AMI is therefore dependent on the use
            of cardiac biomarkers and biosensors. These techniques   The authors declare no conflicts of interest.


            Volume 2 Issue 2 (2023)                         8                        https://doi.org/10.36922/gtm.0403
   21   22   23   24   25   26   27   28   29   30   31